Introduction: Illicit opioid use has become a state of emergency in Canada, with an alarming number of people being diagnosed with Opioid Use Disorder (OUD). Medication Assisted Treatment (MAT) is a common treatment for those with OUD. However, there is substantial variability in the treatment outcomes used to evaluate the effectiveness of MAT, making it difficult to establish a clinically and scientifically relevant and reproducible treatment effect.
the scientific community, as well as dissemination of information to service users through study reports, community presentations and resources in primary care settings.
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ARTICLE SUMMARY

Strengths and limitations of this study
Strengths
• This will be the first systematic review examining any patient important outcomes that have been reported relating to the efficacy of MAT among people with opioid use disorder.
• Additional qualitative distributions will be examined based on study age group (adolescents, adults), sex, country and type of MAT.
Limitations
• There may be variability in how treatment outcomes are measured in studies, which may pose a challenge in the qualitative synthesis and thematic analysis.
• There may be a paucity in patient important outcomes reported in the published clinical trials testing the effectiveness of medication assisted treatment for opioid use disorder.
INTRODUCTION Rationale
Illicit opioid use has become a state of emergency in Canada, with an alarming number of people being diagnosed with Opioid Use Disorder (OUD) (1, 2) . Between 2015 and 2016, approximately one in seven people in Ontario filled an opioid prescription, which the Canadian (4) . Such an increase in opioid use is concerning, as opioid poisonings have resulted in more than 16 hospitalizations a day in Canada (5) . From 2007 From -2008 to [2014] [2015] , the crude rate of hospitalizations due to opioid poisonings increased by over 30% (6) . According to the national report on opioid-related deaths, there were 3987 opioid-related fatalities in Canada in 2017 alone (7) . Based on this count, the apparent opioid-related death rate in Canada was 8.8 per 100,000 that year (7) . Considering the substantial health risk opioids pose in Canada, it is vital to identify effective ways of treating OUD and enhancing patients' recovery and treatment outcomes.
Currently, there are over 65,000 patients in Ontario and British Columbia combined seeking pharmacological treatment for opioid use disorder, most commonly via Methadone Maintenance Treatment (MMT) (8) (9) (10) . MMT is the oldest and one of the most commonly used treatment for OUD. However, it is one of several Medication Assisted Treatment (MAT) options available (11, 12) . MAT range from a variety of treatments available including opioid agonists such as methadone and buprenorphine/ naloxone to opioid antagonists such as naltrexone (12, 13) .
Recent guidelines indicate there is little consistent evidence to evaluate the effectiveness of MATs (14) . Reviews evaluating MAT effectiveness have found great variability in outcomes between studies (15) (16) (17) , making it difficult to establish a real treatment effect. Each study measures a different set of treatment outcomes that define success in arbitrary or convenient terms. This is a substantial limitation in addiction research that must be overcome to reach a consensus on which treatment outcome domains should be the goals, how those outcome domains should be measured, and what works for opioid addiction management. Who decides on what outcome is important? As a healthcare provider, one might consider abstinence the ultimate goal of addiction treatment, while a patient may desire control over their substance use or symptom management to be the goal of treatment. Additionally, researchers must consider how trial design is influenced by selection of outcomes. If the outcome for such trials was reduced criminal activity, reduced incidence of infectious diseases, reduced homelessness, or other social advantage, the intervention may be helpful for only certain groups of patients. Regardless, without the identification of a measurable treatment outcome that has an impact and significance to patients, services, and the population as a whole, all the investment in trials will result in inadequate and inconsistent "efficacy" with limited, if any, external validity. There needs to be a set of established MAT outcomes, so that healthcare providers and their patients, pharmacotherapeutics developers, policy makers, researchers, budget holders and service users are able to evaluate the true effectiveness of these therapies.
While establishing empirical outcomes for MATs is crucial, it is also vital to understand which treatment outcomes the patients consider important. Clinicians, researchers, patients and other stake holders may have different views in in this regard, and thus a comprehensive assessment of what outcomes should be considered especially taking the patients' perspective must be included. Unfortunately, patient-centered outcomes are often neglected in efficacy trials, an issue especially marked within the addiction literature. A recent systematic review evaluating the effectiveness of different MATs for OUD suggests the literature has no consistent definition of a "successful" addiction treatment outcome, and thus most trials assessing therapy effectiveness use a variety of end points (18) . Treatment attrition, continued opioid use, criminal activities, quality of life, and economic costs are among the long list of outcomes utilized across trials aimed to establish treatment effectiveness in the OUD literature. There are also very few validated tools such as the Addiction Severity Index (19) (20) which measure health improvement across various domains. The variation in the selection of outcomes and the many different ways of defining and measuring those outcomes call for a need to determine a set of outcomes that are patient informed in addiction treatment. To our knowledge, an evaluation of patients' treatment goals is often embedded in larger studies, and thus has not been investigated in a systematic review.
Objectives
The purpose of this systematic review and meta-analysis is to investigate the outcomes currently used to measure MAT effectiveness, and to identify patient relevant outcomes to enhance the effectiveness of current treatment options.
Specifically, our objectives are to:
1.
Summarize all treatment outcome domains used in clinical trials to measure MAT effectiveness for OUD and how these outcomes are assessed.
2.
Summarize the observational and qualitative literature reporting patient-identified important treatment outcome domains for OUD.
METHODS AND ANALYSIS
This protocol was reported using the Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) statement (21)
Eligibility criteria
The first search strategy will include randomized controlled trials (RCTs) examining any and all treatment outcomes of OUD MAT. There will be no restriction on age of the study 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   8 participants, as described above. Studies will be excluded if they are animal studies or are incomplete studies (i.e. pilot, preliminary reports).
The second search strategy will include observational studies and qualitative research that examine what outcomes are important to patients in MATs regarding treatment success. Similar to the first strategy, there will be no restriction on age.
Outcomes and prioritization
The first objective will assess which outcomes are currently being used in randomized controlled trials to measure the effectiveness of MAT. For example, these outcomes may include continued opioid use, other substance use, physical adverse events (i.e. emergency room visits, hospitalizations), social adversity (i.e. criminal activity, unemployment, marital discord) and mortality.
The second objective will be based on observational and qualitative studies and will determine which outcomes patients have indicated are important for them while receiving MAT.
These outcomes may include, for example, securing employment, reducing intravenous drug use, regaining custody of children, and reducing withdrawal symptoms.
Information sources
We will be searching the following databases for this review: MEDLINE, EMBASE, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9 Platform (WHO ICTRP). Articles will be obtained using comprehensive search strategies (Table   1 and 2). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Data management
An online platform, Google Forms, will be utilized in managing the articles and will allow the entire team to collaborate and easily access the articles. The team will be trained on how to use Google Forms. A calibration stage with 25 articles will take place to evaluate the level of agreement for the study form.
Selection process
For each research question, two reviewers will independently conduct title and abstract screening, and subsequently full text screening of those citations deemed potentially eligible. We will refer to the inclusion and exclusion criteria to assess study eligibility during screening.
Disagreements between reviewers will be resolved by discussion to consensus, or by consulting a third author if it remains unresolved. We will assess agreement between reviewers and report the The second research question will use a similar data extraction template, with the exception that outcomes assessed in the study that patients consider important for treatment will be extracted. Additionally, the second objective will include qualitative research. Themes based on patient-important outcomes will be extracted. The data extraction forms for both objectives will be pilot tested by two independent reviewers to determine their feasibility for this review.
Risk of bias in individual studies
Two reviewers will independently assess the methodological quality of eligible studies for this review. We will use the Cochrane Risk of Bias Tool to assess the risk of bias for RCTs (23) .
We will conduct subgroup analyses based on risk of bias assessment scores for studies scoring 6 points or higher on the Cochrane Risk of Bias Tool, which are standard cut offs used in previous reviews (18) . The Newcastle-Ottawa Scale will be used to assess the risk of bias for observational studies(24) and will conduct subgroup analyses based on risk of bias assessment scores for studies scoring 5 or lower.
Data synthesis
Results from the first objective will be summarized qualitatively. This analysis will involve summary descriptions of all outcomes identified and used, the treatment domains of outcomes, summaries of the rationales provided for using said outcomes to measure treatment effectiveness.
We will also summarize any psychometric properties associated with any outcome reported.
Meanwhile, results from the second research question will be summarized qualitatively. Patientimportant outcomes will be reviewed and grouped using a thematic analysis. Themes will emerge as the data are analyzed, but some examples that may arise include drug-related outcomes, social outcomes, physical health outcomes, and occupational outcomes.
Data Statement
When the review is complete, any additional data can be made available upon request.
Confidence in cumulative evidence
As we are purely reviewing what outcomes are reported and how these outcomes are measured for efficacy of MAT, we will not need to determine strength of evidence using The
Grading of Recommendations Assessment, Development and Evaluation (GRADE)(25).
Patient and Public Involvement
As this is a protocol for a systematic review, there will be no patient or public involvement at this stage. 
ETHICS AND DISSEMINATION
This study has planned and integrated a knowledge translation component. The primary end users of this information are clinicians, researchers, and patients who use MAT. As such, we have chosen a knowledge users panel designing the review question and implementation. The goal is to broadly disseminate the synthesized information to improve the way treatment effectiveness is evaluated in MAT. We will collaborate primarily with the CATC, Canadian
Centre for Substance Use and Addiction (CCSA), and addiction services in British Columbia (Dr. Launette Rieb, addiction medicine) to disseminate the findings of this review by releasing summary reports and creating resources for knowledge users to access the information easily.
We plan to share the results of our study through educational workshops for healthcare providers, such as primary care physicians, addiction specialists, service managers and researchers. We will also disseminate the information to the scientific community via peer reviewed publications and conference presentations.
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Instructions to authors
Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.
Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.
Upload your completed checklist as an extra file when you submit to a journal.
In your methods section, say that you used the PRISMA-P reporting guidelines, and cite them as: Dissemination strategies will involve sharing study results through workshops, presentations, peer-reviewed publications, study reports, community presentations and resources in primary care settings.
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ARTICLE SUMMARY
Strengths and limitations of this study
Strengths  This will be the first systematic review examining any patient important outcomes that have been reported relating to the effectiveness of MAT among people with opioid use disorder.
 Additional qualitative distributions will be examined based on study age group (adolescents, adults), sex, country and type of MAT.
Limitations
 There may be variability in how treatment outcomes are measured in studies, which may pose a challenge in the qualitative synthesis and thematic analysis.
 There may be a paucity in patient important outcomes reported in the published clinical trials testing the effectiveness of medication assisted treatment for opioid use disorder. (6) . According to the national report on opioid-related deaths, there were 3987 opioid-related fatalities in Canada in 2017 alone (7) . Based on this count, the apparent opioid-related death rate in Canada was 8.8 per 100,000 that year (7) . Considering the substantial health risk opioids pose in Canada, it is vital to identify effective ways of treating OUD and enhancing patients' recovery and treatment outcomes.
INTRODUCTION Rationale
Recent guidelines indicate there is little consistent evidence to evaluate the effectiveness of MATs (14) . Reviews evaluating MAT effectiveness have found great variability in outcomes between studies(15-17), making it difficult to establish a real treatment effect. Each study measures a different set of treatment outcomes that define success in arbitrary or convenient terms. This is a substantial limitation in addiction research that must be overcome to reach a (20) which measure health improvement across various domains. The variation in the selection of outcomes and the many different ways of defining and measuring those outcomes call for a need to determine a set of outcomes that are patient informed in addiction treatment. To our knowledge, an evaluation of patients' treatment goals is often embedded in larger studies, and thus has not been investigated in a systematic review.
Objectives
1. Summarize all treatment outcome domains used in clinical trials to measure MAT effectiveness for OUD and how these outcomes are assessed.
2.
Summarize the observational and qualitative literature reporting patient-identified important treatment outcome domains (goals and markers that patient identify as a measure of success fort themselves) for OUD.
METHODS AND ANALYSIS
This protocol was reported using the Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) statement (21) 
Eligibility criteria
The first search strategy will include randomized controlled trials (RCTs) examining any and all treatment outcomes of OUD MAT. There will be no restriction on age of the study participants, as described above. Studies will be excluded if they are animal studies or are incomplete studies (i.e. internal pilot, preliminary reports). Furthermore, if multiple studies have been published using the same registration number, only the most recent will be included.
The second search strategy will include observational studies (excluding case studies, case series, and reviews) and qualitative research, such as, but not limited to, interviews and focus groups, that examine what outcomes are important to patients in MATs regarding treatment success. Similar to the first strategy, there will be no restriction on age.
Outcomes and prioritization
These outcomes may include, for example, securing employment, reducing intravenous drug use, regaining custody of children, and reducing withdrawal symptoms. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Platform (WHO ICTRP). Articles will be obtained using comprehensive search strategies (Table   1 and 2). We will search databases from inception to the date the search is ran. We have created the two searches to reflect the most encompassing terms thus far but will include the final strategies for all databases in the full review. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The first strategy (Table 1) includes search terms related to MAT and randomized control trial, and their medical subject headings (MeSH) in varying combinations, while the second strategy (Table 2) includes terms related to MAT and patient important outcomes in various combinations. Additionally, we will manually search through reference lists of articles that pass the initial abstract screening for any relevant articles the search strategy may not have captured.
Information sources
An experienced health sciences librarian will be consulted when devising the strategies and conducting the search in the identified databases. A broad search strategy will be employed to include titles, abstracts, and keyword fields. No demographic or language constraints will be included in the search strategy, as OUD impacts individuals of all ages and nationalities. The searches will be limited to human studies.
Data management
An online platform, Google Forms, will be utilized in managing the articles and will allow the entire team to collaborate and easily access the articles. The team will be trained on how to use 
Selection process
Disagreements between reviewers will be resolved by discussion to consensus, or by consulting a third author if it remains unresolved. We will assess agreement between reviewers and report the kappa statistic within our results. A flow diagram (Figure 1 ) outlining the screening process, as well as a detailed table of included studies following the final screening stage will be included, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (22) . We will use ENDNOTE (x8) program to collect publication records, identify duplicates, find full text files, and organize the articles for full text extraction.
Data collection process
For the first research question, full text data extraction forms will be constructed to include the following information: author, year of study, country, title of journal, number of participants, type of population (clinical, community, or institutional), mean age and other demographic data of participants, study methodology (single arm, double-arm or triple-arm), type of OSAT (methadone, buprenorphine, heroin etc.), dose and duration of treatment, outcomes assessed in the study, and the various measures used. The types of details for the measured outcomes will The second research question will use a similar data extraction template, with the exception that outcomes assessed in the study that patients consider important for treatment will be extracted. Additionally, the second objective will include qualitative research. Themes based on patient-important outcomes will be extracted. The data extraction forms for both objectives will be pilot tested by two independent reviewers to determine their feasibility for this review. For both research questions, data will be extracted in duplicate to ensure accuracy.
Risk of bias in individual studies
Two reviewers will independently assess the methodological quality of eligible studies for this review. We will use the Cochrane Risk of Bias Tool to assess the risk of bias for RCTs(23).
We will conduct subgroup analyses based on risk of bias assessment scores for studies scoring 6 points or higher on the Cochrane Risk of Bias Tool, which are standard cut offs used in previous reviews (18) . The Newcastle-Ottawa Scale will be used to assess the risk of bias for observational studies (24) and will conduct subgroup analyses based on risk of bias assessment scores for studies scoring 5 or lower.
Data synthesis
Meanwhile, results from the second research question will be summarized qualitatively. Patient- important outcomes will be reviewed and grouped using a thematic analysis. Themes will emerge as the data are analyzed, but some examples that may arise include drug-related outcomes, social outcomes, physical health outcomes, and occupational outcomes.
Data Statement
Confidence in cumulative evidence
As we are purely reviewing what outcomes are reported and how these outcomes are measured for effectiveness of MAT, we will not need to determine strength of evidence using
The Grading of Recommendations Assessment, Development and Evaluation (GRADE)(25).
Patient and Public Involvement
As this is a protocol for a systematic review, there will be no patient or public involvement at this stage.
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Instructions to authors
In your methods section, say that you used the PRISMA-P reporting guidelines, and cite them as: Search strategy #10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated 9
Study recordsdata management #11a Describe the mechanism(s) that will be used to manage records and data throughout the review
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